Systematix Sees Dr Reddy’s Stock Rising 10–15% if Biosimilar Wins December Approval
Systematix analyst Vishal Manchanda says Dr Reddy’s stock could advance 10–15% if a major drug approval materialises in December 2026. The company has resolved semaglutide manufacturing challenges and is ready to resume supply.
Dr Reddy's Laboratories (DRL) could see its stock advance by 10-15% if a major drug approval materialises in December 2026, according to Vishal Manchanda, Pharma Analyst at Systematix Group. The pharmaceutical major has resolved its semaglutide manufacturing challenges and is ready to resume suppli…